As enclosed.

November 07, 2026 To To The Secretary The Secretary National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Trading Symbol: DIVISLAB Scrip Code: 532488 Dear Sir / Madam, Sub: Outcome of Board Meeting held on November 07, 2026 Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Further to our letter dated October 22, 2026, we would like to inform that the Board of Directors of the Company at its meeting held on November 07, 2026, has approved, inter alia, the following items of business: Financial Results Approved the unaudited financial results for the quarter and half year ended September 30, 2026. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Statement of unaudited standalone financial results for the quarter and half year ended September 30, 2026 and Limited Review Report of the Statutory Auditors thereon. 2. Statement of unaudited consolidated financial results for the quarter and half year ended September 30, 2026 and Limited Review Report of the Statutory Auditors thereon. 3. Press release on financial results. The Board meeting commenced at 10.30 Hrs and concluded at 11.40 Hrs. This is for your information and records. Thanking you, Yours faithfully, For Divi's Laboratories Limited M.Satish Choudhury Company Secretary & Compliance Officer DIVl'S LABO RAT ORIES LIMITED STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30™ SEPTEMBER,2026 (Rs. in Crores) Quarter ended Half Year ended Year ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Income Revenue from operations 3647 2974 2660 6621 5017 10388 Other income 88 63 146 144 265 506 Total income 3735 3037 2806 6765 5282 10894 2 Expenses a) Cost of materials consumed 1803 1495 907 3298 1896 4260 b) Purchases of stock-in-trade - - - - - - c) Changes in inventories of finished goods, work-in- progress and stock-in-trade (630) (567) 144 (1197) 72 (244) d) Employee benefits expense 428 397 344 825 674 1400 e) Depreciation and amortisation expense 142 132 113 274 225 461 f) Finance costs 13 6 8 19 11 23 g) Other expenses 459 409 370 861 737 1484 Total expenses 2215 1872 1886 4080 3615 7384 3 Profit before exceptional Items and tax (1-2) 1520 1165 920 2685 1667 3510 4 Exceptional items-Impact of new labour codes - - - - - 74 5 Profit before tax (3-4) 1520 1165 920 2685 1667 3436 6 Tax expense a) Current tax 370 290 220 660 411 869 b) Deferred tax 10 (16) 4 (6) 3 (40) Total tax expense 380 274 224 654 414 829 Profit for the period/year (5-6) 1140 891 696 2031 1253 2607 8 Other comprehensive income: Items that will not be reclassified to Profit or Loss: (i) Gain/(Loss) on Remeasurement of post- employment benefit obligation 2 2 -* 4 (1) 8 (ii) Income tax relating to the above -* (I) -* (1) -* (2) Total other comprehensive income (i+ii) 2 1 -* 3 (1) 6 9 Total comprehensive income for the period/year (7+8) 1142 892 696 2034 1252 2613 10 Paid-up Equity Share Capital (Face Value: Rs. 2/- per share) 53 53 53 53 53 53 11 Other equity excluding revaluation reserve 16658 12 Earnings per Share # (Face Value: Rs. 2/-per share) (not annualized) a) Basic (Rs.) 42.97 33.55 26.24 76.52 47.19 98.19 b) Diluted (Rs.) 42.97 33.55 26.24 76.52 47.19 98.19 DIVl'S LABORATORIES LIMITED STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES AS AT 30™ SEPTEMBER,2026 (Rs in Crores) As at S.No. Particulars 30.09.2026 31.03.2026 (Unaudited) (Audited) A ASSETS 1 Non-current assets Property, plant and equipment 7451 6514 Capital work-in-progress 1638 2113 Intangible assets 15 6 Financial assets a) Investments 78 76 b) Other financial assets 72 67 Income tax assets (net) - 1 Other non-current assets 257 143 Sub-total: Non-current assets 9511 8920 2 Current assets Inventories 5325 3711 Financial assets a) Trade receivables 3705 3228 b) Cash and cash equivalents 248 85 c) Bank balances other than (b) above 1933 3286 d) Other financial assets 6 8 Income-tax assets (net) - 14 Other current assets 1150 702 Sub-total: Current assets 12367 11034 TOTAL ASSETS 21878 19954 B EQUITY AND LIABILITIES 1 Equity Equity Share Capital 53 53 Other Equity 17895 16658 Sub-total: Total Eauitv 17948 16711 2 Liabilities Non-current liabilities Financial liabilities a) Other financial liabilities 477 456 Provisions 83 81 Deferred tax liabilities (net) 464 469 Other non-current liabilities 233 218 Sub-total: Non-current liabilities 1257 1224 3 Current liabilities Financial liabilities a) Borrowings - - b) Trade payables Total outstanding dues of micro and small enterprises 71 62 Total outstanding dues other than above 1658 1128 c) Other financial liabilities 396 460 Provisions 64 60 Current tax liabilities (net) 81 11 Other current liabilities 403 298 Sub-total: Current liabilities 2673 2019 Total Liabilities 3930 3243 TOTAL EQUITY AND LIABILITIES 2187~-~> ==:--·<:· ' 19954 DIVl'S LABORATORIES LIMITED STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 301h SEPTEMBER 2026 (Rs. in Crores) For the year For the Half year ended ended Particulars 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Audited) A. Cash flow from operating activities Profit before tax 2685 1667 3436 Adjustments for: Depreciation and amortisation expense 274 225 461 Unrealised foreign exchange (gain)/ loss 88 (44) (106) Interest income from financial assets at amortised cost (115) (157) (284) Change in fair value of investment in optionally convertible debentures (2) (2) (4) Interest expense 19 5 23 Provision for doubtful debts/(written back) including bad debts written off/ (recovered) -* 2 1 Loss/(gain) on disposal/ discard of property, plant and equipment and intangible assets 4 -* -* Amortisation of government grants -* -* -* 2953 1696 3527 Change in operating assets and liabilities (Increase) /Decrease in trade receivables (578) 150 (261) (Increase) /Decrease in inventories (1614) (207) (678) (Increase) /Decrease in other financial assets (3) 5 3 (Increase) /Decrease in other assets (436) (137) (334) Increase /(Decrease) in employee benefit obligation 10 6 95 Increase /(Decrease) in trade payables 552 147 303 Increase/ (Decrease) in other financial liabilities (58) 260 478 Increase /(Decrease) in other liabilities 120 88 440 Cash generated from operations 946 2008 3573 Income taxes paid including withholding tax and net ofrefunds (576) (368) (862) Net cash inflow from operating activities 370 1640 2711 B. Cash flow from investing activities Payments for property, plant and equipment (871) (1544) (2519) Proceeds from sale of property, plant and equipment - 3 3 Interest received 115 158 284 Proceeds from withdrawal of deposits 3776 2855 6156 Investment in deposits (2423) (2733) (6142) Net cash inflow/(outflow) from investing activities 597 (1261) (2218) Cash flow from financing activities Proceeds /(repayment) of working capital loans (net) - 83 - Interest paid (7) (5) (5) Dividend paid to company's shareholders (797) (796) (797) Net cash outflow from financing activities (804) (718) (802) DIVl'S LABORATORIES' LIMITED STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026 (Rs. in Crores) For the year For the Half year ended ended Particulars 30.09.2026 • 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Audited) Net increase/(decrease) in cash and cash equivalents (A+B+C) 163 (339) (309) Cash and cash equivalents at the beginning of the period/year 85 394 394 Cash and cash equivalents at end of the period/year 248 55 85 Reconciliation of cash and cash equivalents at the end of the period/ year Cash and cash equivalents as per Balance sheet 248 61 85 Overdraft facilities from bank - (6) - Balance as per Sta [Showing first 8,000 characters — download PDF for full document]